This is believed to be related to the HIF-1α–VEGF–ANG-1 axis.33There is also evidence that VEGF might be regarded as a therapeutic target candidate to inhibit bone resorption, angiogenesis, as well as immune responses in periodontitis, periimplantitis, and apical periodontitis.10Intriguingly, a previous study found that combining anti-VEGF bevacizumab with moxifloxacin on weekly basis along with standard care resulted in rapid regression of highly expressed VEGF-tubercular granulomas.34 This evidence concerns the gene HIF1A and periapical periodontitis.